MINNEAPOLIS — Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc. The transaction consideration includes an upfront payment of $250 million plus an additional $325 million that can be maximally earned through calendar year 2022 upon reaching certain performance milestones. With this acquisition, Minneapolis-based Bio-Techne now has a world-wide workforce […]

Funding will support development of a Pseudomonas aeruginosa targeted therapeutic, to tackle the genetic cause of antibiotic resistance CAMBRIDGE, UK – Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing a novel platform technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, today announced that it had been awarded significant funding to support […]

Day-One Lab Readiness speeds commercialization and reimbursement in personalized medicine Hilden, Germany, and Tokyo, Japan – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration with SRL, Inc., the largest clinical testing laboratory company in Japan, to prepare for introduction of new companion diagnostics simultaneous with new drug approvals. The non-exclusive master collaboration agreement for clinical laboratory […]

Covaris and Bioz Have Partnered to Bring Data and Transparency to the Customer Experience    LOS ALTOS, CA – Bioz, Inc., a Silicon Valley AI data company, is proud to announce a new partnership with Covaris, Inc., the gold standard of DNA fragmentation in Next Generation Sequencing. By combining the latest advances in Natural Language Processing […]

PALO ALTO, CALIFORNIA – Centrillion Technologies, an innovator in building transformative genomic analysis tools announced that it has entered into a partnership with WeDoctor Holdings Limited (“WeDoctor”), China’s leading technology-enabled medical and healthcare solutions platform. The strategic cooperation agreement includes a multi-million US dollar investment by WeDoctor and establishes with Centrillion (Hangzhou) Co., Ltd. a joint […]

HSINCHU, TAIWAN– Centrillion Technologies Taiwan, an innovator in the development and commercialization of transformative genomic analysis tools announced today that it has received a strategic investment from the Arm IoT Fund. With this capital investment, Centrillion Taiwan will continue to expand its manufacturing subsidiary in Hsinchu, Taiwan.   As the largest chipset provider for big data, […]

With the new software version, single cell isolation is now easier, more straight-forward and more precise than ever before.   MUNICH, Germany — Today, MMI launched their latest development, the MMI CellTools 5.0 software platform. With more than 25 years of customer-focused innovation and continuous improvements, the software is now easier and more straight-forward to use. […]

Cambridge, UK Fluidic Analytics Ltd, has announced the issuance of US Patent 9,952,22 B2, entitled ‘Fluidic Separation and Detection’, from the United States Patent and Trademark Office. This paves the way for the development and commercialisation of a next-generation protein analysis technology platform to be launched later this year. “The issuance of the US Patent […]

The new 16-well model uses a proprietary noninvasive biosensor technology to quantify cell proliferation, morphology changes, and adhesion in a label-free, real-time manner. xCELLigence S16 SAN DIEGO ACEA Biosciences, is a privately owned biotechnology company which develops cutting edge instrumentation for cell analysis. The company has just introduced the xCELLigence RTCA S16, which the ideal […]

Providing more affordable full-length single-cell mRNA sequencing with industry-leading coverage and sensitivity for in-depth cellular characterization SOUTH SAN FRANCISCO, Calif. — Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced a new full-length single-cell mRNA sequencing application for the C1™ system that provides deep coverage and high sensitivity while reducing sample preparation costs […]